NovoCure (NVCR) EBIAT (2016 - 2025)
Historic EBIAT for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to -$37.3 million.
- NovoCure's EBIAT fell 2191.69% to -$37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$177.6 million, marking a year-over-year decrease of 1860.41%. This contributed to the annual value of -$168.6 million for FY2024, which is 1855.46% up from last year.
- Latest data reveals that NovoCure reported EBIAT of -$37.3 million as of Q3 2025, which was down 2191.69% from -$40.1 million recorded in Q2 2025.
- In the past 5 years, NovoCure's EBIAT ranged from a high of -$4.1 million in Q1 2021 and a low of -$65.9 million during Q4 2024
- Its 5-year average for EBIAT is -$33.6 million, with a median of -$34.3 million in 2025.
- Per our database at Business Quant, NovoCure's EBIAT tumbled by 104183.34% in 2023 and then surged by 4187.36% in 2024.
- NovoCure's EBIAT (Quarter) stood at -$26.5 million in 2021, then tumbled by 40.99% to -$37.3 million in 2022, then decreased by 26.21% to -$47.1 million in 2023, then plummeted by 40.02% to -$65.9 million in 2024, then soared by 43.46% to -$37.3 million in 2025.
- Its EBIAT was -$37.3 million in Q3 2025, compared to -$40.1 million in Q2 2025 and -$34.3 million in Q1 2025.